Transgene SA

SynShark and Phylloceuticals To Co-Develop Squalene

Retrieved on:

Mercredi, mars 30, 2022

SynShark and Phylloceuticals have announced the formation of a strategic partnership that is likely to change the way squalene, a critical immunologic adjuvant, is manufactured in the future.

Key Points:

SynShark and Phylloceuticals have announced the formation of a strategic partnership that is likely to change the way squalene, a critical immunologic adjuvant, is manufactured in the future.
Phylloceuticals is a leader in plant-based pharmaceutical manufacturing, with a mission to supply underserved world markets to gain access to needed medicine.
SynShark was founded to find new manufacturing platforms to replace or replenish currently unsustainable resources such as squalene.
Plant-based production of squalene is the first of many cutting edge extracts and bio-actives SynShark will launch to replace unsustainable sourcing.

Transgene and BioInvent Receive IND Approval from the U.S. FDA for BT-001, a Novel Oncolytic Virus for the Treatment of Solid Tumors

Retrieved on:

Jeudi, mai 27, 2021

Biotechnology, FDA, Health, Pharmaceutical, Oncology, Virotherapy, Experimental cancer treatments, Biotechnology, Medicine, Oncolytic virus, Life sciences, Health care, Transgene SA, Pexastimogene devacirepvec

This IND will allow patients in the U.S. to be enrolled into the ongoing Phase I/IIa clinical trial of this novel oncolytic virus BT-001.

Key Points:

This IND will allow patients in the U.S. to be enrolled into the ongoing Phase I/IIa clinical trial of this novel oncolytic virus BT-001.
Hedi Ben Brahim, Chairman and CEO of Transgene, said: We have designed BT-001 to significantly improve treatment for patients with solid tumors by restoring their immune response against cancer.
We are pleased to receive IND approval for this Phase I/IIa clinical trial of BT-001, which is BioInvents fourth clinical program.
The scientific and clinical development of the oncolytic virus candidate BT-001 is a 50/50 collaboration between BioInvent and Transgene.

Global Oncolytic Virus Therapy Clinical Trials Research Immunotherapy Market Insight 2026

Retrieved on:

Lundi, avril 19, 2021

Virotherapy, Clinical medicine, Medicine, Biotechnology, Experimental cancer treatments, Life sciences, Oncolytic virus, Talimogene laherparepvec, Immunotherapy, Akseli Hemminki, Transgene SA

b'"Global Oncolytic Virus Immunotherapy Market, Dosage, Price & Clinical Trials Outlook 2026" Report Highlights:\nGlobal Oncolytic Virus Immunotherapy Market: US$ 700 Million Opportunity\nGlobal Oncolytic Virus Immunotherapy Clinical Trials: >125 Therapies In Trials\nUSA Dominates Oncolytic Virus Immunotherapy Clinical Trials: >50 Therapies In Trials\nImlygic (Talimogene laherparepvec) & Oncorine: Dosage, Price & Patent insight\nThe ability of the researchers to use viral particle for enhancing the immune response against the cancer cells is estimated to get recognized as a unique platform for treating cancer patients.

Key Points:

b'"Global Oncolytic Virus Immunotherapy Market, Dosage, Price & Clinical Trials Outlook 2026" Report Highlights:\nGlobal Oncolytic Virus Immunotherapy Market: US$ 700 Million Opportunity\nGlobal Oncolytic Virus Immunotherapy Clinical Trials: >125 Therapies In Trials\nUSA Dominates Oncolytic Virus Immunotherapy Clinical Trials: >50 Therapies In Trials\nImlygic (Talimogene laherparepvec) & Oncorine: Dosage, Price & Patent insight\nThe ability of the researchers to use viral particle for enhancing the immune response against the cancer cells is estimated to get recognized as a unique platform for treating cancer patients.
Global oncolytic virus immunotherapy market is a novel cancer treatment platform which is engineered to deliver maximum results for the cancer patients in a controlled way.
In a more efficient way, the therapy at clinical levels has led to the significant advancement of the global cancer therapeutics market.
All these are witnessed to be inclining the market towards high growth rate and market size in the future years.\nThe current clinical market associated with global oncolytic virus immunotherapy is estimated to be the result of extensive clinical research activities that have been conducted by the researchers all across the globe.

Global Oncolytic Virus Therapy Clinical Trials Research Immunotherapy Market Insight 2026

Retrieved on:

Dimanche, avril 18, 2021

Virotherapy, Clinical medicine, Medicine, Biotechnology, Experimental cancer treatments, Life sciences, Oncolytic virus, Talimogene laherparepvec, Immunotherapy, Akseli Hemminki, Transgene SA

b'"Global Oncolytic Virus Immunotherapy Market, Dosage, Price & Clinical Trials Outlook 2026" Report Highlights:\nGlobal Oncolytic Virus Immunotherapy Market: US$ 700 Million Opportunity\nGlobal Oncolytic Virus Immunotherapy Clinical Trials: >125 Therapies In Trials\nUSA Dominates Oncolytic Virus Immunotherapy Clinical Trials: >50 Therapies In Trials\nImlygic (Talimogene laherparepvec) & Oncorine: Dosage, Price & Patent insight\nThe ability of the researchers to use viral particle for enhancing the immune response against the cancer cells is estimated to get recognized as a unique platform for treating cancer patients.

Key Points:

b'"Global Oncolytic Virus Immunotherapy Market, Dosage, Price & Clinical Trials Outlook 2026" Report Highlights:\nGlobal Oncolytic Virus Immunotherapy Market: US$ 700 Million Opportunity\nGlobal Oncolytic Virus Immunotherapy Clinical Trials: >125 Therapies In Trials\nUSA Dominates Oncolytic Virus Immunotherapy Clinical Trials: >50 Therapies In Trials\nImlygic (Talimogene laherparepvec) & Oncorine: Dosage, Price & Patent insight\nThe ability of the researchers to use viral particle for enhancing the immune response against the cancer cells is estimated to get recognized as a unique platform for treating cancer patients.
Global oncolytic virus immunotherapy market is a novel cancer treatment platform which is engineered to deliver maximum results for the cancer patients in a controlled way.
In a more efficient way, the therapy at clinical levels has led to the significant advancement of the global cancer therapeutics market.
All these are witnessed to be inclining the market towards high growth rate and market size in the future years.\nThe current clinical market associated with global oncolytic virus immunotherapy is estimated to be the result of extensive clinical research activities that have been conducted by the researchers all across the globe.

Global Oncolytic Virus Therapy Immunotherapy Market USD 700 Million Opportunity

Retrieved on:

Jeudi, mars 25, 2021

Health sciences, Clinical medicine, Medicine, Virotherapy, Biotechnology, Experimental cancer treatments, Oncolytic virus, Talimogene laherparepvec, Therapy, Virus, Immunotherapy, Transgene SA

NEW DELHI, March 25, 2021 /PRNewswire/ -- "Global Oncolytic Virus Immunotherapy Market, Dosage, Price & Clinical Trials Outlook 2026" Report Highlights:

Key Points:

NEW DELHI, March 25, 2021 /PRNewswire/ -- "Global Oncolytic Virus Immunotherapy Market, Dosage, Price & Clinical Trials Outlook 2026" Report Highlights:
Global Oncolytic Virus Immunotherapy Market: US$ 700 Million Opportunity
Global Oncolytic Virus Immunotherapy Clinical Trials: >125 Therapies In Trials
USA Dominates Oncolytic Virus Immunotherapy Clinical Trials: >50 Therapies In Trials
Imlygic (Talimogene laherparepvec) & Oncorine: Dosage, Price & Patent insight
Oncolytic virus therapy constitutes of using the clinical benefits of virus for treating different diseases and specifically cancer in the pharmaceutical industry.
In addition, the annual growth rate set by the oncolytic virus therapy is also estimated to align the entire therapy as a self-sufficient therapy with or without combination.
In the research and development base for global oncolytic virus therapy, the therapy due to its widespread applications is receiving tons of investments which is however inclining the therapy market to get emerged as a therapy with numerous blockbuster products against different types of diseases.
In driving the entire oncolytic virus therapy at global level, there are numerous advantages that are associated with it.

Global Oncolytic Virus Therapy Immunotherapy Market USD 700 Million Opportunity

Retrieved on:

Jeudi, mars 25, 2021

Health sciences, Clinical medicine, Medicine, Virotherapy, Biotechnology, Experimental cancer treatments, Oncolytic virus, Talimogene laherparepvec, Therapy, Virus, Immunotherapy, Transgene SA

NEW DELHI, March 25, 2021 /PRNewswire/ -- "Global Oncolytic Virus Immunotherapy Market, Dosage, Price & Clinical Trials Outlook 2026" Report Highlights:

Key Points:

NEW DELHI, March 25, 2021 /PRNewswire/ -- "Global Oncolytic Virus Immunotherapy Market, Dosage, Price & Clinical Trials Outlook 2026" Report Highlights:
Global Oncolytic Virus Immunotherapy Market: US$ 700 Million Opportunity
Global Oncolytic Virus Immunotherapy Clinical Trials: >125 Therapies In Trials
USA Dominates Oncolytic Virus Immunotherapy Clinical Trials: >50 Therapies In Trials
Imlygic (Talimogene laherparepvec) & Oncorine: Dosage, Price & Patent insight
Oncolytic virus therapy constitutes of using the clinical benefits of virus for treating different diseases and specifically cancer in the pharmaceutical industry.
In addition, the annual growth rate set by the oncolytic virus therapy is also estimated to align the entire therapy as a self-sufficient therapy with or without combination.
In the research and development base for global oncolytic virus therapy, the therapy due to its widespread applications is receiving tons of investments which is however inclining the therapy market to get emerged as a therapy with numerous blockbuster products against different types of diseases.
In driving the entire oncolytic virus therapy at global level, there are numerous advantages that are associated with it.

Liver Cancer Tumors Appear to Be Resistant to Immunotherapy in Patients With Underlying Non-alcoholic Steatohepatitis (NASH)

Retrieved on:

Mercredi, mars 24, 2021

Medical specialties, Hepatology, Clinical medicine, Medicine, Hepatocellular carcinoma, Liver cancer, Brachyury, Cancer, Ultrasonography of liver tumors, Transgene SA

The researchers led a large international collaboration to investigate immunotherapy's effect on hepatocellular carcinoma (HCC), a deadly liver cancer, caused by NASH.

Key Points:

The researchers led a large international collaboration to investigate immunotherapy's effect on hepatocellular carcinoma (HCC), a deadly liver cancer, caused by NASH.
"These results also highlight the need for refined therapeutic strategies aimed at treating both the tumor as well as the microenvironment associated with distinct underlying liver disease."
While immunotherapy has clinical benefit for hepatocellular carcinoma, this study's findings are important because a quarter of all HCC patients have NASH.
The meta-analysis in this study was conducted on three high-quality phase 3 trials that included more than 1,600 HCC patients treated with anti-PD1 immunotherapy.

DGAP-News: Abivax follows DSMB recommendation to stop the phase 2b/3 miR-AGE Covid-19 clinical trial due to lack of efficacy

Retrieved on:

Vendredi, mars 5, 2021

Abivax, Medical specialties, Hepatocellular carcinoma, Cancer, Clinical medicine, Medicine, Autoimmune diseases, Transgene SA, COVID-19 drug repurposing research

The study has a robust randomized, double-blind and placebo-controlled design to test whether ABX464 could prevent the development of severe Covid-19 disease in the participants.

Key Points:

The study has a robust randomized, double-blind and placebo-controlled design to test whether ABX464 could prevent the development of severe Covid-19 disease in the participants.
The DSMB recommendation is based on a planned, interim analysis evaluating data of 305 high-risk Covid-19 patients who completed the study period.
Abivax, a clinical stage biotechnology company, is modulating the body's natural immune machinery to treat patients with chronic inflammatory diseases, viral infections, and cancer.
Based in Paris and Montpellier, Abivax has two drug candidates in clinical development, ABX464 to treat severe inflammatory diseases, and ABX196 to treat hepatocellular carcinoma.

Transgene and BioInvent Have Enrolled First Patient in Phase I/IIa Trial of Novel Oncolytic Virus BT-001 in Solid Tumors

Retrieved on:

Lundi, mars 1, 2021

Oncology, Health, Other Health, Clinical trials, Pharmaceutical, Biotechnology, Health sciences, Health, Gene delivery, Oncolytic virus, Life sciences, Transgene, Clinical trial, Transgene SA

BT-001 is being co-developed through a 50/50 collaboration between BioInvent and Transgene.

Key Points:

BT-001 is being co-developed through a 50/50 collaboration between BioInvent and Transgene.
Hedi Ben Brahim, Chairman and CEO of Transgene, said: We are excited to start this clinical trial with BT-001, which is the result of a very productive collaboration between Transgene and BioInvent.
The inclusion of the first patient in this Phase I/IIa trial marks a further broadening of our clinical pipeline, which now comprises three candidate products and four clinical studies.
The scientific and clinical development of the oncolytic virus candidate BT-001 is a 50/50 collaboration between BioInvent and Transgene.

Transgene and BioInvent Receive Approval From ANSM to Proceed With Phase I/IIa Trial of Anti-CTLA4-armed Oncolytic Virus BT-001 in Solid Tumors

Retrieved on:

Mardi, janvier 19, 2021

Oncology, Health, Other Health, Clinical trials, Pharmaceutical, Biotechnology, Cancer treatments, Clinical medicine, Medicine, Virotherapy, Experimental cancer treatments, Biotechnology, Oncolytic virus, Pembrolizumab, Transgene SA, Pexastimogene devacirepvec

BT-001 is a highly innovative oncolytic virus, that has been designed to achieve a strong anti-tumor response by combining multiple mechanisms of action.

Key Points:

BT-001 is a highly innovative oncolytic virus, that has been designed to achieve a strong anti-tumor response by combining multiple mechanisms of action.
This international study will enroll up to 48 patients with metastatic/advanced solid tumors in its Phase I part followed by expansion cohorts in its Phase IIa part.
The trial is a multicenter, open-label, dose-escalation Phase I/IIa trial evaluating BT-001 alone or in combination with pembrolizumab.
The scientific and clinical development of the oncolytic virus candidate BT-001 is a 50/50 collaboration between BioInvent and Transgene.